vs
Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $4.8M, roughly 1.9× MAXCYTE, INC.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -200.5%, a 140.1% gap on every dollar of revenue. On growth, MAXCYTE, INC. posted the faster year-over-year revenue change (-20.9% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-2.9M). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -7.4%).
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
MXCT vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $9.1M |
| Net Profit | $-9.6M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | -234.5% | -51.1% |
| Net Margin | -200.5% | -60.3% |
| Revenue YoY | -20.9% | -49.9% |
| Net Profit YoY | 9.4% | -184.8% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.8M | $9.1M | ||
| Q3 25 | $4.6M | $17.9M | ||
| Q2 25 | $5.8M | $15.7M | ||
| Q1 25 | $5.7M | $10.1M | ||
| Q4 24 | $6.1M | $18.2M | ||
| Q3 24 | $5.6M | $18.0M | ||
| Q2 24 | $5.0M | $13.5M | ||
| Q1 24 | $5.6M | — |
| Q4 25 | $-9.6M | $-5.5M | ||
| Q3 25 | $-12.4M | $2.4M | ||
| Q2 25 | $-12.4M | $164.0K | ||
| Q1 25 | $-10.3M | $-3.6M | ||
| Q4 24 | $-10.6M | $6.5M | ||
| Q3 24 | $-11.6M | $3.2M | ||
| Q2 24 | $-9.4M | $-2.2M | ||
| Q1 24 | $-9.5M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | -234.5% | -51.1% | ||
| Q3 25 | -307.4% | 11.9% | ||
| Q2 25 | -244.3% | 7.5% | ||
| Q1 25 | -214.1% | -41.0% | ||
| Q4 24 | -213.1% | 39.6% | ||
| Q3 24 | -250.4% | 22.2% | ||
| Q2 24 | -241.0% | -18.0% | ||
| Q1 24 | -219.8% | — |
| Q4 25 | -200.5% | -60.3% | ||
| Q3 25 | -269.7% | 13.2% | ||
| Q2 25 | -212.2% | 1.0% | ||
| Q1 25 | -178.7% | -35.8% | ||
| Q4 24 | -175.0% | 35.6% | ||
| Q3 24 | -205.9% | 18.0% | ||
| Q2 24 | -188.8% | -16.4% | ||
| Q1 24 | -170.6% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | $-0.12 | $0.03 | ||
| Q2 25 | $-0.12 | $0.00 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $-0.11 | $0.03 | ||
| Q2 24 | $-0.09 | $-0.03 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.0M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.5M | $48.2M |
| Total Assets | $202.5M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.0M | $14.7M | ||
| Q3 25 | $105.7M | $13.6M | ||
| Q2 25 | $126.6M | $17.9M | ||
| Q1 25 | $138.3M | $19.5M | ||
| Q4 24 | $154.5M | $19.8M | ||
| Q3 24 | $153.8M | $27.4M | ||
| Q2 24 | $157.3M | $23.4M | ||
| Q1 24 | $157.5M | — |
| Q4 25 | $171.5M | $48.2M | ||
| Q3 25 | $180.3M | $52.9M | ||
| Q2 25 | $190.7M | $49.9M | ||
| Q1 25 | $199.4M | $45.2M | ||
| Q4 24 | $206.3M | $43.2M | ||
| Q3 24 | $213.3M | $32.4M | ||
| Q2 24 | $221.3M | $28.6M | ||
| Q1 24 | $226.4M | — |
| Q4 25 | $202.5M | $82.3M | ||
| Q3 25 | $213.5M | $82.3M | ||
| Q2 25 | $219.8M | $78.5M | ||
| Q1 25 | $230.0M | $73.9M | ||
| Q4 24 | $239.5M | $73.4M | ||
| Q3 24 | $248.6M | $61.6M | ||
| Q2 24 | $251.5M | $91.5M | ||
| Q1 24 | $257.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.7M | $2.0M |
| Free Cash FlowOCF − Capex | $-2.9M | $1.6M |
| FCF MarginFCF / Revenue | -61.0% | 17.8% |
| Capex IntensityCapex / Revenue | 4.8% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-36.2M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.7M | $2.0M | ||
| Q3 25 | $-7.5M | $-3.7M | ||
| Q2 25 | $-9.9M | $-5.2M | ||
| Q1 25 | $-14.4M | $-5.1M | ||
| Q4 24 | $-7.8M | $4.0M | ||
| Q3 24 | $-4.4M | $4.1M | ||
| Q2 24 | $-4.8M | $-3.6M | ||
| Q1 24 | $-10.6M | — |
| Q4 25 | $-2.9M | $1.6M | ||
| Q3 25 | $-7.8M | $-4.2M | ||
| Q2 25 | $-10.4M | $-5.7M | ||
| Q1 25 | $-15.1M | $-5.4M | ||
| Q4 24 | $-8.0M | $3.6M | ||
| Q3 24 | $-4.8M | $4.0M | ||
| Q2 24 | $-5.1M | $-3.8M | ||
| Q1 24 | $-11.4M | — |
| Q4 25 | -61.0% | 17.8% | ||
| Q3 25 | -168.5% | -23.7% | ||
| Q2 25 | -179.2% | -36.2% | ||
| Q1 25 | -262.3% | -53.0% | ||
| Q4 24 | -131.6% | 19.6% | ||
| Q3 24 | -85.5% | 22.4% | ||
| Q2 24 | -103.3% | -28.1% | ||
| Q1 24 | -203.6% | — |
| Q4 25 | 4.8% | 4.4% | ||
| Q3 25 | 6.5% | 2.8% | ||
| Q2 25 | 10.0% | 2.8% | ||
| Q1 25 | 11.4% | 3.0% | ||
| Q4 24 | 2.4% | 2.3% | ||
| Q3 24 | 7.2% | 0.5% | ||
| Q2 24 | 5.9% | 1.3% | ||
| Q1 24 | 14.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MXCT
| Products | $4.2M | 87% |
| Other | $634.0K | 13% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
